Easton Pharmaceuticals' goal is to utilize the transdermal delivery system to rapidly develop and commercialize a portfolio of products that target various skin and tissue conditions. Current products in development are focused on areas where there are limited product offerings or unmet medical needs: scars and stretch marks, varicose veins and cellulite.


Note: ViorraTM will be launched in two phases. EP-001 is the current formula and EP-002 will have consumer benefits substantiated by the clinical trials and consumer research.